What’s BridgeBio Pharma Inc. (BBIO)’s Price to Earnings Ratio?

0
13

BridgeBio Pharma Inc. (NASDAQ:BBIO) saw an upside of 11.38% to close Tuesday at $9.49 after adding $0.97 on the day. The 5-day average trading volume is 1,332,360 shares of the company’s common stock. It has gained $9.59 in the past week and touched a new high 2 times within the past 5 days. An average of 1,403,900 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,260,762.

BBIO’s 1-month performance is 14.89% or $1.61 on its low of $6.64 reached on 12/28/22. The company’s shares have touched a 52-week low of $4.98 and high of $12.64, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, BBIO has achieved 24.54% or $1.87 and has reached a new high 7 times. However, the current price is down -24.91% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

BBIO stock investors last saw insider trading activity on Jan 05.STEPHENSON BRIAN C (Secretary, Treasurer & CFO) most recently sold 61,040 shares at $7.67 per share on Jan 05. This transaction cost the insider $468,470. CEO and President, Kumar Neil, sold 120,000 shares at a price of $7.67 on Jan 05. Then, on Nov 17, CEO and President Kumar Neil sold 34,640 shares at a price of $9.40 per share. This transaction amounted to $325,606.

Valuation Metrics

BBIO stock has a beta of 0.62. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 15.46.

BridgeBio Pharma Inc.’s quick ratio for the period ended June 29 was 5.40, with the current ratio over the same period at 5.40.. In terms of profitability, the gross margin trailing 12 months is 95.10%. The firm’s gross profit as reported stood at $66.6 million against revenue of $69.72 million.

Earnings Surprise

For the quarterly period ending June 29 this year, BridgeBio Pharma Inc.’s cash and short-term investments amounted to $75.08 million against total debt of $1.71 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -13.54% to -$137.34 million, while revenue of -$9.86 million was 92.82% off the previous quarter. Analysts expected BBIO to announce -$0.63 per share in earnings in its latest quarter, but it posted -$0.07, representing a 88.90% surprise. EBITDA for the quarter stood at more than -$127.47 million. BBIO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.86 billion, with total debt at $1.71 billion. Shareholders hold equity totaling $149.48 million.

Let’s look briefly at BridgeBio Pharma Inc. (BBIO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 69.91% to suggest the stock is trending Neutral, with historical volatility in this time period at 70.89%.

The stock’s 5-day moving average is $8.60, reflecting a +9.33% or $0.81 change from its current price. BBIO is currently trading +14.06% above its 20-day SMA, -8.22% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +12.04% and SMA200 by-21.83%.

Stochastic %K and %D was 76.86% and 68.42% and the average true range (ATR) pointed at 0.64. The RSI (14) points at 61.90%, while the 14-day stochastic is at 96.11% with the period’s ATR at 0.65. The stock’s 9-day MACD Oscillator is pointing at 0.24 and 0.59 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for BridgeBio Pharma Inc. (NASDAQ: BBIO), SVB Leerink reiterated its an Outperform rating for the company but lifted their price target by $66 to $24.

LEAVE A REPLY

Please enter your comment!
Please enter your name here